Mato, A., Svoboda, J., Luning Prak, E., Schuster, S., Tsao, P., Dorsey, C., Sarmasti, L., Becker, P., Brander, D., Nasta, S., Landsburg, D., King, C., Morrigan, B., Elwell, J., Kennard, K., Roeker, L., Zelenetz, A., Purdom, M., Paskalis, D., Sportelli, P., Miskin, H., Weiss, M., & Shadman, M. (n.d.). pHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. Hematological oncology, 37, 119–120. http://access.bl.uk/ark:/81055/vdc_100086208575.0x00003d